New data at ASCO and EHA highlight clonoSEQ MRD test's key role in blood cancer treatment and research.

Adaptive Biotechnologies announced that its clonoSEQ test for measurable residual disease (MRD) will feature in 33 presentations at ASCO and EHA 2026, reinforcing its role as a gold standard in blood cancer care. The test aids in assessing treatment response and guiding therapy decisions across multiple blood cancers like multiple myeloma, CLL, ALL, and lymphoma. New data show clonoSEQ's growing global impact and its integration into clinical practice and research, supporting personalized treatment approaches. This highlights the increasing adoption of MRD-guided care driven by biopharma investments and advances in next-generation sequencing technology.